4 Morris EJ, Ji J-Y, Yang F, Di Stefano L, Herr A, Moon NS, Kwon EJ, Haigis KM, Näär AM, Dyson NJ. E2F1
represses beta-catenin transcription and is antagonized by both pRB and CDK8. Nature 2008;455(7212):552-
556.
5 Alarcón C1, Zaromytidou AI, Xi Q, Gao S, Yu J, Fujisawa S, Barlas A, Miller AN, Manova-Todorova K,
Macias MJ, Sapkota G, Pan D, Massagué J. Nuclear CDKs drive Smad transcriptional activation and turnover
in BMP and TGF-beta pathways. Cell 2009;139(4):757-769.
6 Donner AJ, Szostek S, Hoover JM, Espinosa JM. CDK8 is a stimulus-specific positive coregulator of p53
target genes. Mol Cell 2007;27(1):121-133.
7 Donner AJ, Hoover JM, Szostek SA, Espinosa JM. Stimulus-specific transcriptional regulation within the p53
network. Cell Cycle 2007;6(21):2594-2598.
8 Donner AJ, Ebmeier CC, Taatjes DJ, Espinosa JM. CDK8 is a positive regulator of transcriptional elongation
within the serum response network. Nat Struct Mol Biol 2010;17(2):194-201.
9 Galbraith MD, Allen MA, Bensard CL, Wang X, Schwinn MK, Qin B, Long HW, Daniels DL, Hahn WC,
Dowell RD, Espinosa JM., HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to
hypoxia. Cell 2013;153(6):1327–1339.
10 Fryer CJ, White JB, Jones KA. Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and
coordinate activation with turnover. Mol Cell 2004;16(4):509–520.
11 Bancerek J, Poss ZC, Steinparzer I, Sedlyarov V, Pfaffenwimmer T, Mikulic I, Dölken L, Strobl B, Müller M,
Taatjes DJ, Kovarik P. CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the
interferon response. Immunity 2013;38(2):250-262.
12 Belakavadi M, Fondell JD. CDK8 positively cooperates with mediator to promote thyroid hormone
receptordependent transcriptional activation. Mol Cell Biol 2010;30(10):2437-2448.
13 Broude EV, Győrffy B, Chumanevich AA, Chen M, McDermott MS, Shtutman M, Catroppo JF, Roninson
IB. Expression of CDK8 and CDK8-interacting Genes as Potential Biomarkers in Breast Cancer. Curr Cancer
Drug Targets. 2015;15(8):739-749.
14 Kim MY, Han SI, Lim SC. Roles of cyclin-dependent kinase 8 and β-catenin in the oncogenesis and
progression of gastric adenocarcinoma. Int J Oncol. 2011;38(5):1375-1383.
15 Kapoor A, Goldberg MS, Cumberland LK, Ratnakumar K, Segura MF, Emanuel PO, Menendez S,
Vardabasso C, Leroy G, Vidal CI, Polsky D, Osman I, Garcia BA, Hernando E, Bernstein E. The Histone
Variant macroH2A Suppresses Melanoma Progression Through Regulation of CDK8. Nature
2010;468(7327):1105-1109.
16 (a) Rzymski T, Mikula M, Wiklik K, Brzózka K. CDK8 kinase - An emerging target in targeted cancer
therapy. Biochim Biophys Acta. 2015;1854(10 Pt B):1617-1629. (b) Pelish HE, Liau BB, Nitulescu II,
Tangpeerachaikul A, Poss ZC, Da Silva DH, Caruso BT, Arefolov A, Fadeyi O, Christie AL, Du K, Banka D,
Schneider EV, Jestel A, Zou G, Si C, Ebmeier CC, Bronson RT, Krivtsov AV, Myers AG, Kohl NE, Kung AL,
Armstrong SA, Lemieux ME, Taatjes DJ, Shair MD. Mediator kinase inhibition further activates super-
enhancer-associated genes in AML. Nature. 2015;526(7572):273-276. (c) Czodrowski P, Mallinger A, Wienke
D, Esdar C, Pöschke O, Busch M, Rohdich F, Eccles SA, Ortiz-Ruiz MJ, Schneider R, Raynaud FI, Clarke PA,
Musil D, Schwarz D, Dale T, Urbahns K, Blagg J, Schiemann K. Structure-Based Optimization of Potent,
Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening. J Med Chem.
2016;59(20):9337-9349. (d) Koehler MF, Bergeron P, Blackwood EM, Bowman K, Clark KR, Firestein R,
Kiefer JR, Maskos K, McCleland ML, Orren L, Salphati L, Schmidt S, Schneider EV, Wu J, Beresini MH.
Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8/19 Knockout Cells. ACS
−228
Med Chem Lett 2016;7(3):223
. (e) Mallinger A, Schiemann K, Rink C, Stieber F, Calderini M, Crumpler
S, Stubbs M, Adeniji-Popoola O, Poeschke O, Busch M, Czodrowski P, Musil D, Schwarz D, Ortiz-Ruiz MJ,
Schneider R, Thai C, Valenti M, de Haven Brandon A, Burke R, Workman P, Dale T, Wienke D, Clarke PA,
Esdar C, Raynaud FI, Eccles SA, Rohdich F, Blagg J. Discovery of Potent, Selective, and Orally Bioavailable
Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19. J Med Chem.
2016;59(3):1078-1101. (f) Bergeron P, Koehler MF, Blackwood EM, Bowman K, Clark K, Firestein R, Kiefer
JR, Maskos K, McCleland ML, Orren L, Ramaswamy S, Salphati L, Schmidt S, Schneider EV, Wu J1, Beresini
M. Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8. ACS Med Chem
Lett. 2016;7(6):595-600. (g) Rzymski T, Mikula M, Żyłkiewicz E, Dreas A, Wiklik K, Gołas A, Wójcik K,
Masiejczyk M, Wróbel A, Dolata I, Kitlińska A, Statkiewicz M, Kuklinska U, Goryca K, Sapała Ł, Grochowska
A, Cabaj A, Szajewska-Skuta M, Gabor-Worwa E, Kucwaj K, Białas A, Radzimierski A, Combik M,
Woyciechowski J, Mikulski M, Windak R, Ostrowski J, Brzózka K. SEL120-34A is a novel CDK8 inhibitor
active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains.
Oncotarget. 2017;8(20):33779-33795.
17 Patent applications describing our CDK8 inhibitors have been published. Assays and full experimental
procedures for analogues in this letter are contained in the patent WO2014154723A1.